Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates

Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00527-18. doi: 10.1128/AAC.00527-18. Print 2018 Sep.

Abstract

Data on the frequency of gyrA and gyrB mutations in fluoroquinolone-resistant isolates of the Mycobacterium avium complex (MAC) and the Mycobacterium abscessus complex (MABC) are limited. In our analysis, we did not find any resistance-associated mutations in gyrA or gyrB in 105 MAC or MABC clinical isolates, including 72 moxifloxacin-resistant isolates. Our findings suggest that mechanisms other than gyrA and gyrB mutations contribute to moxifloxacin resistance in these organisms.

Keywords: Mycobacterium abscessus complex; Mycobacterium avium complex; gyrase mutation; moxifloxacin; resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • DNA Gyrase / genetics*
  • Drug Resistance, Bacterial / genetics*
  • Fluoroquinolones / therapeutic use
  • Humans
  • Microbial Sensitivity Tests / methods
  • Moxifloxacin / therapeutic use*
  • Mutation / genetics*
  • Mycobacterium abscessus / genetics*
  • Mycobacterium avium Complex / genetics*
  • Mycobacterium avium-intracellulare Infection / microbiology

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • DNA Gyrase
  • Moxifloxacin